← Eichor
Study identifier: NCT06338072 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Impact of the Menstrual Cycle in Reproductive Aged Women With Type 1 Diabetes Using a Closed Loop System (DIABETEXX/1).

Condition: Type 1 Diabetes  ·  Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

PhaseN/A
Planned participants119
Who can joinAll sexes, 18 Years to 50 Years
Healthy volunteersNo

About this study

The aim of this observational study is to assess the effectiveness of automatic insulin infusion in responding to changes in insulin sensitivity throughout various phases of the menstrual cycle in a cohort of reproductive-aged women with type 1 diabetes, using an advanced closed-loop system. By gaining insights into both the limitations and effectiveness of this adaptation, we aim to inform the enhancement of control algorithms and learning strategies within closed-loop systems. This research is especially vital for addressing the distinct challenges that women commonly encounter in maintaining glycemic control.

This description comes directly from the study's public registry record.

Talk to the study team

Lía Nattero-Chávez, MD.PhD  ·  marialia.nattero@salud.madrid.org

Esther De la calle, MD.  ·  esther.delacalle@salud.madrid.org

Always discuss trial participation with your own doctor first.

Locations (1)

Lía Nattero-ChávezMadrid, Madrid, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06338072